Abstract:Molecular profiling is limited by tumor heterogeneity and access to sufficient tissue for comprehensive analysis. Circulating tumor DNA (ctDNA) is promising as a minimally-invasive liquid biopsy for testing gene alterations and monitoring personalised treatment strategies. Because of its high expense, translation of the sensitive and accurate next generation sequencing (NGS) into routine cancer care has been slow. We retrospectively reviewed 60 advanced NSCLC pts who were performed gene test prior to treatment using tissue by ARMS. Blood collections (10ml K2-EDTA) were performed after disease progression and analysed by NGS using a 10-gene panel (EGFR, KRAS, BRAF, HER2, PIK3CA, ALK, ROS1, RET, MET and TP53). We evaluated the significance of the outcome of panel testing by NGS in guiding the subsequent treatment in clinical practice. Among 60 NSCLC pts, 39 were male, 28 were never-smokers, and 56 were adenocarcinoma. ctDNA profiling detected alterations in 50 pts (83%). TP53 (53%), EGFR (48%) and KRAS (15%) were the most common abnormalities detected. Additionally, MET (8%), ALK (3%), HER2 (3%) and PIK3CA (2%) mutations were detected, respectively. Sensitizing mutations were detected in 22 pts (37%) prior to treatment using tissue by the method of ARMS, including 20 EGFR mutations and 2 ALK fusions, and all pts received tyrosine kinase inhibitor (TKI) as first-line therapy. Among 20 EGFR mutant pts, T790M mutation was detected in 9 pts (45%), KRAS mutation was detected in 4 pts (20%), and TP53 mutation was detected in 12 pts (60%), while MET amplification was found in 1 pt (5%). 1 KRAS mutation and 1 TP53 mutation were detected in 2 ALK –TKI resistant pts, respectively. 28 pts (47%) reported as tissue negative had a positive liquid biopsy, including 4 MET 14 exon skipping mutations, 2 EGFR 19 DEL, 4 EGFR L858R and 1 EGFR L861Q, and 2 EGFR T790M mutations. The mutation abundance is all below 1%, except 2 EGFR 19 DEL and 4 L858R. Ten pts received TKIs; 2 got parcial responses, 5 stable diseases and 3 progressive disease. ctDNA can be used as a ‘liquid biopsy’ for molecular profiling of NSCLC pts, and NGS, as a highly sensitive method to detect mutations with low mutation abundance, can provide more chances to pts to receive precise treatment.

Can Peripheral Blood Be Used As Surrogate in Detecting Epidermal Growth Factor Receptor Mutation Status in Advanced Non-Small Cell Lung Cancer Patients? A Meta-Analysis

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Reliability of Using Circulating Tumor Cells for Detecting Epidermal Growth Factor Receptor Mutation Status in Advanced Non-Small-cell Lung Cancer Patients: a Meta-Analysis and Systematic Review

Comparison of Different Methods for Detecting Epidermal Growth Factor Receptor Mutations in Peripheral Blood and Tumor Tissue of Non-Small Cell Lung Cancer As A Predictor of Response to Gefitinib

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

[The Detection by Denaturing High Performance Liquid Chromatography of Epidermal Growth Factor Receptor Mutation in Tissue and Peripheral Blood from Patients with Advanced Non-Small Cell Lung Cancer].

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

Rapid Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Using Real-Time Polymerase Chain Reaction with TaqMan-MGB Probes.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Blood As A Substitute For Tumor Tissue In Detecting Egfr Mutations For Guiding Egfr Tkis Treatment Of Nonsmall Cell Lung Cancer A Systematic Review And Meta-Analysis

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.

A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer

Tissue or Blood: Which is More Suitable for Detection of EGFR Mutations in Non-Small Cell Lung Cancer?

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.